(Las Vegas, Nevada, United States) “Small Cell Lung Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Small Cell Lung Cancer Market.
The Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Small Cell Lung Cancer Pipeline Report:
Companies across the globe are diligently working toward developing novel Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years.
Small Cell Lung Cancer companies working in the treatment market are Rhizen Pharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, Akeso, Ascentage Pharma, BioNTech, Qilu Pharmaceutical Co, Amgen, BeiGene, Sorrento Therapeutics, and others, are developing therapies for the Small Cell Lung Cancer treatment
Emerging Small Cell Lung Cancer therapies such as – RP12146, SYHA 1807, AK104, APG 1252, BNT 411, QL1706, Tarlatamab, Tislelizumab, Socazolimab, and others are expected to have a significant impact on the Small Cell Lung Cancer market in the coming years.
In March 2022, For the treatment of adult patients with metastatic Small-cell Lung Cancer (SCLC) who have disease progression during or after receiving platinum-based chemotherapy, Luye Pharma Group has filed a New Drug Application (NDA) in Hong Kong, China. PharmaMar has licenced the novel oncology medication lurbinectedin to Luye Pharma
In March 2022, The FDA has designated HPN328, a delta-like ligand 3- (DLL3) targeting TriTAC®, as an orphan drug for the treatment of small-cell lung cancer (SCLC), according to a statement from Harpoon Therapeutics, Inc. HPN328 is presently the subject of a Phase 1/2 clinical investigation in SCLC patients.
In March 2022, Akeso, Inc. announced that it has entered into a collaboration agreement with Shenzhen Chipscreen Biosciences, Ltd. (SHA Code 688321) to conduct a Phase Ib/II clinical study of combination therapy of Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104) and Chiauranib (a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor) in patients with ES-SCLC which progressed on combination therapy of platinum-based chemotherapy and PD-(L)1 inhibitor as first-line treatment.
In July 2021, In order to treat patients with untreated advanced stage Small Cell Lung Cancer, Sorrento Therapeutics started a Phase III, randomised, double-blind, placebo-controlled study of Carboplatin Plus Etoposide with or without ZKAB001 (Anti-PD-L1 Antibody). The treatment cycle for eligible patients will be every three weeks, and they will be randomly assigned to receive ZKAB001+ carboplatin + etoposide or placebo + carboplatin + etoposide
Small Cell Lung Cancer Overview
Because the cancer cells exhibit characteristics of both nerve cells and endocrine (hormone-secreting) cells, small cell lung cancer is classified as a neuroendocrine carcinoma. Specialised tissue called endocrine tissue contains cells that secrete hormones. These hormones serve a number of purposes in the body.
Get a Free Sample PDF Report to know more about Small Cell Lung Cancer Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/small-cell-lung-cancer-pipeline-insight
Emerging Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:
RP12146: Rhizen Pharmaceuticals
SYHA 1807: CSPC ZhongQi Pharmaceutical Technology
APG 1252: Ascentage Pharma
BNT 411: BioNTech
QL1706: Qilu Pharmaceutical Co
Socazolimab: Sorrento Therapeutics
Route of Administration
Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Products have been categorized under various Molecule types, such as
Small Cell Lung Cancer Pipeline Therapeutics Assessment
Small Cell Lung Cancer Assessment by Product Type
Small Cell Lung Cancer By Stage and Product Type
Small Cell Lung Cancer Assessment by Route of Administration
Small Cell Lung Cancer By Stage and Route of Administration
Small Cell Lung Cancer Assessment by Molecule Type
Small Cell Lung Cancer by Stage and Molecule Type
DelveInsight’s Small Cell Lung Cancer Report covers around 100+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Small Cell Lung Cancer product details are provided in the report. Download the Small Cell Lung Cancer pipeline report to learn more about the emerging Small Cell Lung Cancer therapies
Some of the key companies in the Small Cell Lung Cancer Therapeutics Market include:
Key companies developing therapies for Small Cell Lung Cancer are – Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Aileron Therapeutics, Ipsen, Celgene, Lee’s Pharmaceutical Limited, AbbVie, Chipscreen Biosciences, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, Amgen, Bristol-Myers Squibb, Genentech, Sorrento Therapeutics, DAIICHI SANKYO COMPANY, BioNTech, Harpoon Therapeutics, Genprex, Inc., Tarveda Therapeutics, Taizhou HoudeAoke Biomedical Co., Ltd., BeiGene, HaiHe Biopharma, Kartos Therapeutics, Inc., Boehringer Ingelheim, Y-mAbs Therapeutics, CStone Pharmaceuticals, EpicentRx, Inc., Pfizer, Mologen, Cybrexa Therapeutics, and many others.
Small Cell Lung Cancer Pipeline Analysis:
The Small Cell Lung Cancer pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Small Cell Lung Cancer Treatment.
Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Small Cell Lung Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Small Cell Lung Cancer drugs and therapies
Small Cell Lung Cancer Pipeline Market Drivers
Rising incidence of Small Cell Lung Cancer, improving Healthcare Infrastructure, demand for New and Effective Drugs are some of the important factors that are fueling the Small Cell Lung Cancer Market.
Small Cell Lung Cancer Pipeline Market Barriers
However, The management of SCLC is problematic due to the aggressive nature of this type of cancer, rise in cost of treatment, poor prognosis of the disease in comparison with non-small cell lung cancer and other factors are creating obstacles in the Small Cell Lung Cancer Market growth.
Scope of Small Cell Lung Cancer Pipeline Drug Insight
Key Small Cell Lung Cancer Companies: Rhizen Pharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, Akeso, Ascentage Pharma, BioNTech, Qilu Pharmaceutical Co, Amgen, BeiGene, Sorrento Therapeutics, and others
Key Small Cell Lung Cancer Therapies: RP12146, SYHA 1807, AK104, APG 1252, BNT 411, QL1706, Tarlatamab, Tislelizumab, Socazolimab, and others
Small Cell Lung Cancer Therapeutic Assessment: Small Cell Lung Cancer current marketed and Small Cell Lung Cancer emerging therapies
Small Cell Lung Cancer Market Dynamics: Small Cell Lung Cancer market drivers and Small Cell Lung Cancer market barriers
Request for Sample PDF Report for Small Cell Lung Cancer Pipeline Assessment and clinical trials
Table of Contents
Small Cell Lung Cancer Report Introduction
Small Cell Lung Cancer Executive Summary
Small Cell Lung Cancer Overview
Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment
Small Cell Lung Cancer Pipeline Therapeutics
Small Cell Lung Cancer Late Stage Products (Phase II/III)
Small Cell Lung Cancer Mid Stage Products (Phase II)
Small Cell Lung Cancer Early Stage Products (Phase I)
Small Cell Lung Cancer Preclinical Stage Products
Small Cell Lung Cancer Therapeutics Assessment
Small Cell Lung Cancer Inactive Products
Company-University Collaborations (Licensing/Partnering) Analysis
Small Cell Lung Cancer Key Companies
Small Cell Lung Cancer Key Products
Small Cell Lung Cancer Unmet Needs
Small Cell Lung Cancer Market Drivers and Barriers
Small Cell Lung Cancer Future Perspectives and Conclusion
Small Cell Lung Cancer Analyst Views
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States